4/4/2013

Pfizer and BIND Therapeutics agreed to collaborate in the development and marketing of Accurins, a new class of highly targeted and programmable treatments, using the latter's Medicinal Nanoengineering platform. The partners will jointly conduct preclinical research, and Pfizer has the right to develop and market the Accurins it chooses. BIND could get $50 million in upfront and development milestone fees from Pfizer. BIND is also eligible to receive around $160 million in regulatory and sales milestone fees for each Accurin that is commercialized, plus sales royalties.

Related Summaries